Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
Not likely to be. As I’ve said before MM’s don’t declare below 10%
Get your point Jiving.
Overall its a benefit to achieve orphan designation (fingers crossed they do so) as it definitely adds value of ten years market protection.
Hopefully we get confirmation that they have submitted the application.
That said I would disagree with Jiving's generic comment 'It seems that Pharma's essentially require this as a necessary condition before examining whether to invest in a new drug.'
Given that orphan drugs are for rare disease only, by nature pharma's can't require orphan designation across the board otherwise all drugs would be orphan and no disease would be rare.
Personally I think it relates to the caution around repurposed drugs and wanting as much certainty around product protection as possible.
From the Allenby note 2 years ago.
'Note that many have Fast Track Designation and/or Orphan Drug Designation factors that can accelerate the review process and extend the period of market/data exclusivity and so this is also an option for NXP002. '
Since then the company has consistently said that they consider it an option.
I doubt you would seek orphan designation before patents are granted, as it would be strange to have the product protected as an orphan drug, but not patent protected.
Furthermore, with orphan designation you need to back up your claims with evidence so its seen as a validation of a drug rather than just patenting a method.
Christ on a bike…. Even Sisyphus didn’t have to suffer this fate.
‘If those words were written in December’
Well since the finals were issued at 7am on 3 January, I’m wondering what basis you have of saying ‘if’ they were written in December. Or perhaps you think they were written on New Year’s Day?
The point about the agm is, if you really cared you’d find the time. Nobody here can answer all your questions, and yet when you have the opportunity to ask them yourself to management you turn it down.
Your posting history shows you’re not that busy.
One of the big positives FX, is that the agm is just over two weeks away so you can ask Dan in person then.
Or maybe, as those words were written in December, the original plan was for outlicensing, but discussions over the past two months have led to fund raising happening first whilst orphan designation and nxp002 is progressed.
"...the Directors have prepared cash fow forecasts covering the period ending 31 December 2024 that take into account the likely run rate on overheads and research and development expenditure and the prudent expectations of income from out-licensing rights to its programmes or a fundraising."
Chab, not sure where anyone was saying funded through 2024.
My commentary was from the 30m odd sales a few weeks ago, my assumption being the conversion of the warrants which would net 85k to the company.
Agreed jiving, under the resolutions NFX could have issued up to 20% of shares in issue, so to only issue 10% shows they only need a specific amount and are confident they don’t need more.
Certain is a queer sort.
Far from bitter I’m actually quite happy funding has been done. Plus they didn’t feel the need to use the full allowance that they could have done.
Lucky you have no interest here then.
The point is you spent an inordinate amount of time here talking about a placing coming up, yet neglected to see on happening in a company you are invested in which saw a 60% drop in the sp!
I think you need to focus on the shares your invested in rather than the ones your not.
They'll close out the placing with shares being admitted next Wednesday, at least its all sorted now.
Good to see that this is all in support of the current discussions with potential partners.
NXP002 European patent is all but confirmed, this will then feed into the Orphan Designation submission.
NXP004 Japanese patent is granted, pending formal confirmation.
Discussions with partners continues alongside these.
Nearly as corrupt as AVCT i guess.
Objective investors don't spend any time looking at shares they've sold, they focus on their current situation. Only emotional investor return to stocks they've sold, usually because they need the comfort blanket of trying to prove themselves correct in selling.
Its simple fear of missing out Robbo, they sold at a big loss and don't want others to have any success as it makes them feel bad about their decision.
Its always a shame when people are so shallow they want others to lose money.
NFTs, you were saying the same thing in June, September, and Decemeber and nothing happened. Thats not you being clever, just you keeping guessing long enough till something happens.
You are the definition of an emotional investor as you wouldn't be here if you didn't have an emotional attachment or fear of missing out.